Literature DB >> 25295829

Fulminant myocarditis associated with the H1N1 influenza virus: case report and literature review.

Maria Lúcia Saraiva Lobo1, Ângela Taguchi1, Heloísa Amaral Gaspar1, Juliana Ferreira Ferranti1, Werther Brunow de Carvalho1, Artur Figueiredo Delgado1.   

Abstract

A case of fulminant myocarditis associated with the H1N1 influenza virus. This case report describes the patient's clinical course and emphasizes the importance of bedside echocardiography as an aid in the early diagnosis and management of children with severe myocardial dysfunction. It also discusses aspects relevant to the treatment and prognosis of fulminant myocarditis. The patient was a female, 4 years and 8 months old, previously healthy and with a history of flu symptoms in the past two weeks. The patient was admitted to the emergency room with signs of hemodynamic instability, requiring ventilatory support and vasoactive drugs. The laboratory tests, chest X-ray and echocardiogram suggested the presence of myocarditis. The test for H1N1 in nasopharyngeal secretions was positive. The patient evolved to refractory cardiogenic shock despite the clinical measures applied and died 48 hours after admission to the intensive care unit. The H1N1 influenza virus is an etiological agent associated with acute myocarditis, but there are few reported cases of fulminant myocarditis caused by the H1N1 virus. The identification of signs and symptoms suggestive of fulminant progression should be immediate, and bedside echocardiography is a useful tool for the early detection of myocardial dysfunction and for therapeutic guidance. The use of immunosuppressive therapy and antiviral therapy in acute myocarditis of viral etiology is controversial; hence,the treatment is based on hemodynamic and ventilatory support. The use of hemodynamic support by extracorporeal membrane oxygenation emerges as a promising treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25295829      PMCID: PMC4188471          DOI: 10.5935/0103-507x.20140046

Source DB:  PubMed          Journal:  Rev Bras Ter Intensiva        ISSN: 0103-507X


  19 in total

Review 1.  Myocarditis.

Authors:  A M Feldman; D McNamara
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

Review 2.  Diagnosis of myocarditis: death of Dallas criteria.

Authors:  Kenneth L Baughman
Journal:  Circulation       Date:  2006-01-31       Impact factor: 29.690

Review 3.  Pandemic preparedness and response--lessons from the H1N1 influenza of 2009.

Authors:  Harvey V Fineberg
Journal:  N Engl J Med       Date:  2014-04-03       Impact factor: 91.245

Review 4.  Diagnosis and treatment of pediatric viral myocarditis.

Authors:  D Levi; J Alejos
Journal:  Curr Opin Cardiol       Date:  2001-03       Impact factor: 2.161

5.  Echocardiographic findings in fulminant and acute myocarditis.

Authors:  G M Felker; J P Boehmer; R H Hruban; G M Hutchins; E K Kasper; K L Baughman; J M Hare
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

6.  Mechanical circulatory support for the treatment of children with acute fulminant myocarditis.

Authors:  B W Duncan; D J Bohn; A M Atz; J W French; P C Laussen; D L Wessel
Journal:  J Thorac Cardiovasc Surg       Date:  2001-09       Impact factor: 5.209

Review 7.  Intravenous immunoglobulin for presumed viral myocarditis in children and adults.

Authors:  J Robinson; L Hartling; B Vandermeer; E Crumley; T P Klassen
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

Review 8.  Cardiovascular manifestations associated with influenza virus infection.

Authors:  Mamas Andreas Mamas; Doug Fraser; Ludwig Neyses
Journal:  Int J Cardiol       Date:  2008-07-14       Impact factor: 4.164

9.  Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis.

Authors:  P R Camargo; R Snitcowsky; P L da Luz; R Mazzieri; M L Higuchi; M Rati; N Stolf; M Ebaid; F Pileggi
Journal:  Pediatr Cardiol       Date:  1995 Mar-Apr       Impact factor: 1.655

Review 10.  Ventilator management in the cardiac intensive care unit.

Authors:  Carlos Corredor; Sian I Jaggar
Journal:  Cardiol Clin       Date:  2013-09-20       Impact factor: 2.213

View more
  8 in total

1.  To: Fulminant myocarditis associated with the H1N1 influenza virus: case report and literature review.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Rev Bras Ter Intensiva       Date:  2015-03-01

2.  New-Onset Myocarditis in an Immunocompetent Adult with Acute Metapneumovirus Infection.

Authors:  Mark A Weinreich; Ahmad Y Jabbar; Nagina Malguria; Robert W Haley
Journal:  Case Rep Med       Date:  2015-09-02

Review 3.  Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy.

Authors:  Lifang Zhao; Zhaoying Fu
Journal:  J Immunol Res       Date:  2018-05-07       Impact factor: 4.818

4.  The Clinical Features of Children With Acute Fulminant Myocarditis and the Diagnostic and Follow-Up Value of Cardiovascular Magnetic Resonance.

Authors:  Jianli Lv; Bo Han; Cuiyan Wang; Jing Wang; Diandong Jiang; Lijian Zhao; Yingchun Yi; Jianjun Zhang
Journal:  Front Pediatr       Date:  2019-10-01       Impact factor: 3.418

5.  Hepatitis E-Induced Acute Myocarditis in an Elderly Woman.

Authors:  Pratim Sengupta; Sumanta Biswas; Tapas Roy
Journal:  Case Rep Gastroenterol       Date:  2019-08-13

6.  A Rare Presentation of Fulminant Viral Myocarditis Associated with H1N1: A Series of Four Cases.

Authors:  Teju P Thomas; Sudhaya Kumar; Ashok Anand; Rajagopal Kiran; Vincy Sabu; Abdul Gaffoor
Journal:  Indian J Crit Care Med       Date:  2019-11

7.  Successful treatment of fulminant myocarditis with intra-aortic balloon pump counterpulsation combined with immunoglobulin and glucocorticoid in a young male adult.

Authors:  Huanhuan Li; Lun Li
Journal:  Front Cardiovasc Med       Date:  2022-07-22

Review 8.  The Role of Non-coding RNAs in Viral Myocarditis.

Authors:  Cong Zhang; Yan Xiong; Lijin Zeng; Zhihua Peng; Zhihao Liu; Hong Zhan; Zhen Yang
Journal:  Front Cell Infect Microbiol       Date:  2020-07-02       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.